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Abstract 
Despite the development of selective BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) 
transforming the management of chronic myeloid leukaemia (CML), therapy-resistant 
leukaemic stem cells (LSCs) persist after TKI treatment and present an obstacle to a CML 
cure. Recently, we and others have made significant contributions to the field by unravelling 
survival dependencies in LSCs to work towards the goal of eradicating LSCs in CML 
patients. In this review, we describe these findings focusing on autophagy and mitochondrial 
metabolism, which have recently been uncovered as two essential processes for LSCs 
quiescence and survival, respectively. In addition, we discuss the therapeutic potential of 
autophagy and mitochondrial metabolism inhibition as a strategy to eliminate CML cells in 
patients where the resistance to TKI is driven by BCR-ABL-independent mechanism(s).  
 
Introduction   
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disease that arises 
following transformation of a haemopoietic stem cell (HSC) by the chimeric oncogene BCR-
ABL. BCR-ABL expression results from a reciprocal translocation between chromosome 9 
and 22 leading to the generation of the abnormal Philadelphia chromosome [1]. In turn, the 
expression and translation of BCR-ABL gives rise to a constitutively active non-receptor 
tyrosine kinase, which is the main driver of the chronic phase (CP) of the disease [2]. The 
majority of newly diagnosed CML patients are in CP, which if not treated, can progress to 
accelerated phase followed by a blast crisis over a 5-year time frame [3]. The development of 
selective BCR-ABL tyrosine kinase inhibitors (TKIs), represented by the first generation TKI 
imatinib and subsequent second and third generation TKIs (i.e. dasatinib, nilotinib, bosutinib, 
ponatinib), have significantly improved the life expectancy of CP CML patients, making 
CML a clinically manageable disorder in the majority (50-70%) of patients [4, 5]. TKIs are 
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highly effective in eliminating dividing cells, yet they fail to eradicate the most primitive, 
quiescent CML leukaemic stem cells (hereafter referred as LSCs). This may ultimately 
promote acquired TKI resistance and drive relapse or disease progression [6]. It has been 
estimated that more than 80% of CML patients that respond to TKI maintain minimal 
residual disease (MRD) due to the presence of therapy-resistant LSCs [7]. Even in patients in 
deep molecular response, where BCR-ABL expression is undetectable by quantitative PCR, 
the existence of LSCs capable of reinitiating the disease has been demonstrated, highlighting 
the relevance of targeting LSCs in order to achieve cure [8]. Furthermore, around 25% of all 
CML patients are refractory to all available TKIs, mainly due to TKI intolerance or resistance 
[9]. In this context, resistance to TKI treatment can be classified in BCR-ABL-dependent or 
BCR-ABL-independent resistance; depending on the mechanism the cells obtain to overcome 
the effects of the drugs. Whereas BCR-ABL-dependent resistance is caused by mutations that 
affect the binding of the TKI to the kinase pocket of BCR-ABL, BCR-ABL-independent 
mechanisms are less well understood. The understanding of these mechanisms, together with 
development of approaches for LSCs elimination, is currently a major challenge for 
researchers working on CML [10].  
 
In recent years, autophagy and mitochondrial metabolism have emerged as two crucial 
processes that cancer cells can use to promote resistance to anti-cancer therapy in several 
settings, including haematological tumours [11-14]. Furthermore, recent studies have 
uncovered that inhibition of either of these processes in combination with TKIs is an effective 
strategy to eliminate therapy-resistant LSCs. Here, we discuss the role of autophagy and 
mitochondrial metabolism in the regulation of LSCs and their utility as therapeutic targets in 
CML.    
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Role and regulation of autophagy in cancer  
Cellular homeostasis involves strict regulation of coordinated mechanisms in order to sustain 
cell health. Autophagy is one of these mechanisms and plays an important role in the 
recycling of intracellular components [15]. The best characterized variant of autophagy, 
macroautophagy (hereafter referred as autophagy), involves the formation of the 
autophagosome, a double membrane structure that engulfs the cargo and delivers it into the 
lysosomes for degradation. One important step in the initiation of autophagy is the activation 
of ULK1, a serine/threonine-protein kinase that forms a complex with ATG13 and FIP200 
and drives autophagosomes formation [16]. Under nutrient replete conditions, mTORC1 
phosphorylates ULK1 and ATG13, inhibiting autophagy initiation [17]. Upon starvation, 
ULK1 is dephosphorylated followed by auto-phosphorylation and phosphorylation of ATG13 
and FIP200, leading to a rapid induction of autophagy [18]. Furthermore, autophagy can be 
enhanced as well by an energetic stress response mediated by the AMP-activated protein 
kinase (AMPK). AMPK is activated in response to a drop in the intracellular levels of ATP 
and stimulates autophagy by inhibiting mTORC1, and also by phosphorylating ULK1, as 
well as class III phosphatidylinositol-3-kinase (PI(3)K/Vps34) and Beclin 1 (BECN1)  [19, 
20]. The complex VPS34-BECN1-ATG14-p150 promotes elongation of forming 
autophagosomes following synthesis of phosphatidylinositol 3-phosphate. Furthermore, 
autophagosome completion is mediated by two ATG7-dependent ubiquitin-like conjugation 
systems: i) the ATG12/ATG5/ATG16  and ii) the conjugation of phosphatidylethanolamine 
to the microtubule-associated protein 1 light chain 3 beta, also known as LC3B [21]. Finally, 
the outer membrane of the autophagosome fuses with the lysosomal membrane to form the 
autolysosome, where the degradation of the autophagic body, together with its cytoplasmic 
content occurs [18]. 
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Although autophagy has long been considered a nonselective catabolic process, more recently 
it was shown to selectively degrade potentially harmful intracellular material. For instance, 
autophagy can eliminate protein aggregates and damaged mitochondria by two processes 
known as aggrephagy and mitophagy respectively [22, 23]. These mechanisms can prevent 
the development of a pro-tumourigenic environment characterized by an accumulation of 
reactive oxygen species (ROS), DNA damage and genomic instability [24, 25]. In line with 
these effects, conditional deletion of the autophagy-related (ATG) genes Atg5 or Atg7 in 
murine models promotes tumour initiation in different tissues such as liver and pancreas [25-
27]. Conversely, several studies demonstrate that autophagy deficiency prevents tumour 
progression towards a malignant phenotype, indicating that cancer cells can take advantage of 
autophagy to develop into a more aggressive tumour [28, 29]. Indeed, the oncogenes H-
ras
V12
, K-ras
V12 
and B-raf
V600 
have been shown to upregulate autophagy, providing cancer 
cells with higher levels of basal autophagy than their normal counterparts [29-31]. These 
results support the concept of a dual role of autophagy in cancer, depending on the type or 
stage of the disease.   
 
Although mTORC1 is constitutively activated in > 70% of all cancers [32], it has been 
reported that mTOR activation and high basal autophagy levels can coexist in the same 
tumour. A possible mechanism involved in this apparent paradox relies on the phosphatase 
PP2A, capable of dephosphorylating ULK1, hence activating autophagy bypassing mTOR-
mediated inhibition of ULK1 [33]. In addition, mTORC1 regulates autophagy at a 
transcriptional level by phosphorylating and inactivating the family of MiT/TFE transcription 
factors [34]. These proteins promote the expression of ATG genes [35, 36]. Interestingly, 
tumour cells can also bypass mTOR-mediated negative regulation on MiT/TFE proteins 
activating autophagy and lysosome gene expression [37]. This way, cancer cells can benefit 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
from both the biosynthetic effects mediated by mTORC1 and the metabolic changes 
associated with autophagy-dependent catabolic processes. These data, together with the fact 
that mutations in ATGs are rare in human cancer [38], indicate that a functional process of 
autophagy is required for cancer progression and support the use of autophagy inhibitors as a 
therapeutic approach for cancer treatment. However, as previously discussed, autophagy 
appears to have a temporal or context-dependent role in different cancers. For example, 
Rosenfeldt et al. showed that in mice bearing oncogenic Kras and lacking p53, autophagy 
deficiency does not block tumour progression but, in contrast, accelerates tumour growth 
[27]. These results highlight the importance of studying the role of autophagy in different 
genetic contexts and robust pre-clinical models before perusing with autophagy inhibition as 
a therapeutic intervention.    
 
Role and regulation of autophagy in CML and LSCs 
In CML, the role BCR-ABL plays in the regulation of autophagy is controversial. It has been 
shown that autophagy is induced in both CML cell lines and LSCs following in vitro 
treatment with imatinib, suggesting that BCR-ABL is a negative regulator of autophagy [12, 
39]. However, other studies demonstrate that expression of this oncogene promotes 
autophagosomes formation and that autophagy is essential for BCR-ABL-dependent 
leukemogenesis [40, 41]. In agreement with the latter, CML
 
cell lines that express high levels 
of BCR-ABL (e.g. K562, KCL22) have a very active autophagy flux, suggesting the 
existence of mechanisms involved in bypassing the negative effects on autophagy mediated 
by BCR-ABL-dependent mTOR activation. Since BCR-ABL
+ 
cells exhibit higher levels of 
ROS than normal cells [42], one possibility is that elevated oxidative stress enhances 
autophagy, directly, or indirectly through AMPK activation, similarly to previous studies 
performed with other models [43] (Figure 1). Interestingly, AMPK is active at basal levels in 
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LSCs in acute myeloid leukaemia (AML) [44], and its activation leads to autophagy 
induction in normal HSCs [45]. Future studies will need to assess whether this important 
metabolic sensor is constitutively active and regulates autophagy in CML LSCs as well. 
 
Rothe and colleagues reported that haematopoietic stem/progenitor cells (CD34
+ 
cells) from 
CML patients express higher levels of key ATG genes compared with CD34
+ 
cells from 
healthy donors [46]. Intriguingly, we have preliminary in vitro data suggesting the TKI 
treatment induces expression of ATG genes in CD34
+
 cells, although interrogation of the 
expression of ATG genes in CD34
+
 cells from CML patients, before and after 7 days of 
imatinib treatment, indicated no significant changes in the expression signature of ATG genes 
[47]. These data suggest that BCR-ABL may regulate autophagy at a transcriptional level in 
CML progenitor cells; however, since autophagy is a very dynamic process, which can be 
rapidly regulated by environmental conditions, further experiments measuring the expression 
of ATG genes following TKI treatment at different time points are required to support this 
conclusion. In this regard, in vivo models have recently been generated to measure autophagy 
flux, using mice expressing the autophagy marker LC3 tagged with GFP. Using this system, 
our data demonstrates increased autophagy flux in the stem/progenitor cells of BCR-ABL 
harbouring mice compared to their wild type counterparts; with the former showing increased 
sensitivity to autophagy inhibitors [48]. Further utilisation of this system will provide a 
suitable model to study the regulation of autophagy in CML LSCs at both, transcriptional and 
post-translational levels.   
 
In CML, the expression of ATG genes has been shown to be upregulated in more primitive 
populations compared to more mature cells [46]. In line with this, our results obtained from 
leukaemic mice expressing GFP-LC3 revealed that LSCs have higher autophagy levels 
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compared to more differentiated cells. Similarly, Warr et al. have shown that normal HSCs 
are poised to rapidly use autophagy as an adaptive stress response and that this pro-
autophagic program is driven by the transcription factor Forkhead box protein O3 (FOXO3A) 
[49]. In CML, BCR-ABL activates AKT which in turn phosphorylates FOXO3A promoting 
its cytoplasmic retention and inactivation. TKI treatment downregulates AKT signalling 
localizing FOXO3A to the nucleus leading to cell cycle arrest [50]. Nevertheless, in a fraction 
of LSCs, FOXO3A is in the nucleus even in the absence of TKIs due to the negative 
regulation of AKT by TGFβ [51]. Therefore, another possible mechanism to explain the 
higher autophagy levels in LSCs compared to normal cells would be the activation of 
FOXO3A mediated by TGFβ, which might bypass the TKI-dependent effects on autophagy 
mediated by BCR-ABL/PIK3/AKT/mTORC1 signalling (Figure 1).  
 
Mice lacking FOXO3A show abnormally high ROS levels, impaired leukaemia initiating 
capacity and myeloproliferation [51, 52]. Similarly, recent results from in vivo studies 
indicate that potent lysosomal inhibition drives LSCs out of quiescence leading to an 
expansion of myeloid progenitors [48]. In addition, these results are in line with previous 
studies in normal HSCs, showing that autophagy deficiency increases oxidative stress and 
rapidly reduces the stem cell pool [53-55]. For future studies, it would be informative to 
investigate whether FOXO3A promotes LSCs maintenance through autophagy and whether 
the exit of quiescence induced by autophagy inhibition is due to an accumulation of ROS in 
LSCs. Interestingly, recent work from Thorburn et al. shows that autophagy can regulate 
apoptosis by degrading cytoplasmic FOXO3A [56]. Therefore, these results regarding the 
link between autophagy, FOXO3A and the maintenance of LSCs warrant further 
investigation.  
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Interplay between autophagy and oxidative stress in LSCs  
Our recent work, using an isotope-assisted metabolomics-based approach, has uncovered an 
increase in mitochondrial oxidative metabolism in LSCs compared to their normal 
counterparts. These results were linked to an increase in mitochondria content and membrane 
potential indicating that LSCs are respiring at a higher level than HSCs [57]. In line with 
these results, Giustacchini et al. recently reported that LSCs displayed a significant 
enrichment for genes associated with oxidative phosphorylation (OXPHOS) and fatty acid 
metabolism when compared with normal HSCs [58]. Interestingly, since mitochondria are a 
major source of ROS [59], these results support a model in which the elevated levels of ROS 
in LSCs compared to normal HSCs [42] might derive from an increase in mitochondria 
respiration. As afore mentioned, autophagy has been shown to be upregulated when levels of 
ROS are high [60]; thus, it is possible that elevated levels of autophagy in LSCs are due to an 
increment in ROS that in turn derives from an increased mitochondrial respiration. Finally, 
high levels of autophagy might be preventing differentiation of LSCs by maintaining the 
levels of ROS below a certain threshold (Figure 2). Importantly, AMPK deletion leads to an 
increase in ROS levels and depletion of AML LSCs [44]. Hence, AMPK might be another 
critical antioxidant factor to sustain the LSC pool. In a similar way to these results described 
in AML LSCs, AMPK could be exerting its antioxidant effects in CML LSCs by generating 
the reducing agent NADPH through upregulation of the pentose phosphate pathway, 
following increased glucose uptake [44]. In addition, mitochondrial ROS have been shown to 
be required for AMPK activation, which triggers a PGC-1α-dependent antioxidant response 
[43]. Therefore, we can speculate that in LSCs, AMPK activity might be as well enhanced by 
an increased in ROS levels and, in turn, AMPK can halt the oxidative stress by both, an 
autophagy dependent mechanism and/or a transcriptional regulation of antioxidant genes 
(Figure 2).  
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One important question that arises from the proposed model would be whether autophagy is 
regulating the levels of ROS in LSCs by degrading mitochondria via mitophagy. In line with 
this, de Almeida et al. demonstrated that HSCs have higher mitochondrial mass and lower 
mitochondrial turnover than mature haematopoietic cells; a contradiction to previously 
established literature [61]. These results suggest that the elevated levels of autophagy 
reported in HSCs compared to their more differentiated counterparts [49] are not indicative of 
mitophagy upregulation. Given that the higher mitochondrial content and activity in LSCs 
compared to HSCs is critical for their survival [57], it is unlikely that the increase of ROS 
generated by mitochondrial respiration in LSCs is counteracted by mitophagy alone. Since 
several studies have previously demonstrated the role of autophagy as a ROS scavenger in 
HSCs and in CML cells [55, 62], this suggests a model in which autophagy regulates 
oxidative stress mainly by other mechanisms than mitochondrial degradation. Such potential 
mechanisms include, autophagy modulating the internal supply of amino acids such as 
glutamine [63], which is the main source of the antioxidant glutathione (GSH), and regulating 
the redox balance by degrading kelch-like ECH-associated protein 1 (KEAP1). Under 
homeostatic conditions, KEAP1 mediates the ubiquitination of the nuclear factor erythroid 2-
related factor 2 (NRF2) leading to its inactivation by proteasomal degradation. Following 
oxidative stress, KEAP1 is sequestered by the autophagy cargo receptor SQSTM1/p62 
leading to the inhibition of the degradation of NRF2 and to its activation. This way, NRF2 
can translocate to the nucleus and upregulate the expression of antioxidant-defence genes, 
such as glutathione peroxidase, superoxide dismutase and thioredoxin [60]. Interestingly, the 
KEAP1-NRF2 system can also regulate oxidative stress by affecting mitochondrial dynamics, 
as active NRF2 has been shown to induce mitophagy through PINK1 (PTEN-induced kinase 
1) transcriptional upregulation [64]. Upon mitochondrial damage, PINK1 is accumulated on 
the mitochondrial surface and recruits PARKIN to ubiquitinate several mitochondrial 
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proteins. Next, these ubiquitinated proteins interact with LC3, coupling the autophagy 
machinery with the damaged or unwanted mitochondria due to be degraded [65]. 
Furthermore, NRF2 also induces mitochondrial biogenesis in vivo [66], and cells from 
KEAP1-knockout mice or treated with KEAP1 inhibitors display an increase in oxidative 
metabolism and ATP levels [67-69], indicating that the NRF2-KEAP1 system is vital to 
maintain the integrity of mitochondria, both at a catabolic and an anabolic level. If NRF2 
proves to be upregulated in LSCs, this could potentially be the reason of the higher 
mitochondrial content and respiration in LSCs compared to their normal counterparts. 
Interestingly, two studies have recently uncovered different mechanisms for mitophagy in 
AML LSCs and HSCs [70, 71], suggesting that this process might be regulated in a context-
dependent manner. Although future studies will help elucidating these puzzling mechanisms 
in different cell types, it is now clear that CML and AML LSCs share a common dependency 
on OXPHOS, which may be a therapeutically exploitable vulnerability. 
 
Targeting therapy-resistant CML cells with second-generation autophagy inhibitors 
It has been previously shown that in CML, TKI treatment enhances autophagy that promotes 
survival and TKI-resistance in LSCs [12]. This study led to the development of the 
randomized Phase II clinical trial CHOICES (ClinicalTrials.gov Identifier: NCT01227135) 
where the efficacy of imatinib versus imatinib plus 800mg/day HCQ was evaluated. 
However, results from this trial, and others recently conducted in other types of cancers, 
suggest that it is unlikely that consistent autophagy inhibition is achieved following HCQ 
treatment, even with the maximum tolerated dose given to patients [72-75]. These results 
highlight the need to develop and investigate more potent and/or selective autophagy 
inhibitors using robust pre-clinical models. In recent investigations, second-generation 
autophagy inhibitors such as Lys05, appear to be promising clinical alternatives to HCQ [76]. 
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These compounds accumulate within and deacidify the lysosome (lysosomotropism), 
resulting in impaired autophagy flux. Lys05 is a dimeric analogue of HCQ, which has shown 
3 to 10-fold more potent effects than HCQ in cancer cell lines. Our recent data show that 
Lys05 achieves autophagy inhibition in LSCs and effectively sensitizes them to TKIs in vitro 
and in vivo [48]. Importantly, combination of TKI with HCQ did not add any effects to TKI 
as a single treatment on LSCs survival. More strikingly, the combination of Lys05 and 
nilotinib showed more selectivity for BCR-ABL
+ 
cells than for wild type cells suggesting the 
existence of a potential therapeutic window.    
 
Importantly, in vivo treatment of leukemic mice with Lys05 results in a reduction of LSCs 
followed by an increase in progenitor cells [48]. From a clinical perspective, these results 
highlight the importance of combining lysosomotropic agents with TKIs. In this context, 
while the lysosomal inhibitor is promoting the exit of quiescence in LSCs leading to a more 
differentiated status, the TKI prevents an accelerated myeloproliferation by exerting its pro-
apoptotic effects in progenitor and mature leukemic cells (Figure 3).  
 
One of the major concerns about the clinical use of HCQ and its derivatives is the high risk of 
retinopathy due to a long-term exposure to the drug [77]. Given that this adverse effect has 
been directly associated with high doses and long duration of the treatment, the use of more 
potent autophagy inhibitors might help achieve the desired effects with lower doses and in a 
shorter time period, potentially mitigating such side effects. Furthermore, we and our 
collaborators have observed that mice treated with high doses of Lys05 developed Paneth cell 
dysfunction characterized by intestinal obstruction [76]. Interestingly, this toxicity 
recapitulates the intestinal phenotype of mice and humans with genetic defects in Atg16L1 
[78] providing an additional evidence that Lys05 targets autophagy in vivo. Such side effects 
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must be considered against the potential benefit to patients when considering the introduction 
of second-generation autophagy inhibitors into the clinical setting.  
 
A relevant clinical question is whether more selective autophagy inhibitors than HCQ and 
Lys05 could provide an effective therapeutic strategy to eliminate LSCs. PIK-III is a recently 
developed autophagy inhibitor, which inhibits the kinase activity of VPS34 leading to a 
defective autophagosomes formation [79]. Results using PIK-III demonstrate that in vitro 
treatment of CML CD34
+ 
cells with this compound reduces the number of cells with capacity 
to engraft and leads to an almost complete elimination of engrafted primitive Philadelphia 
positive cells when combined with TKI. Although the chemical properties of PIK-III are not 
suitable for in vivo studies, new derivatives have already been developed with oral 
bioavailability and remain to be tested in CML models [80].  
 
As previously mentioned, around 25% of CML patients develop mechanisms of resistance to 
TKI that are independent on BCR-ABL activity, many of which remain poorly understood. 
Of note, combined mTOR and autophagy inhibition has shown to be effective in targeting 
TKI-resistant CML cells [81]. Interestingly, Rebecca et al. recently identified palmitoyl-
protein thioesterase 1 (PPT1), as a molecular target for dimeric quinacrines, which are more 
potent analogues of HCQ and Lys05 [82]. Strikingly, inhibition of PPT1 has a dual effect; 
inactivates mTORC1 by disrupting its lysosomal localization and de-acidifies the lysosomes, 
which leads to a block in the autophagic flux. Since inhibition of mTOR with single agents 
induces cytoprotective autophagy and has largely failed as an efficient therapy for cancer, 
targeting PPT1 with dimeric quinacrines may offer a new and effective way to overcome 
BCR-ABL independent resistance in CML patients.  
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Targeting therapy-resistant CML cells with inhibitors of oxidative phosphorylation 
Cancer cells reprogram their metabolic pathways to adapt to their high energy demands and 
sustain their uncontrolled proliferation [83]. Thus, identifying metabolic differences between 
normal and transformed cells provides an attractive opportunity to selectively target cancer 
cells. As previously discussed, LSCs display a higher mitochondrial respiration and have a 
greater expression of OXPHOS-related genes compared with normal HSCs [57, 58]. We have 
recently exploited this OXPHOS dependent metabolic vulnerability in LSCs by inhibiting 
mitochondrial metabolism using the antibiotic tigecycline [57]. Of clinical relevance, the 
combination of tigecycline and imatinib was able to eradicate LSCs and prevent disease 
relapse in pre-clinical patient-derived xenograft (PDX) model. Importantly, a minimal effect 
was found in normal HSCs following in vivo treatment indicating the existence of a 
therapeutic window. These results, together with the fact that tigecycline has already been 
approved by the FDA, point to the combination of tigecycline and imatinib as a suitable 
clinical approach to eliminate disease persistence in CML patients. However, results from an 
already conducted phase I clinical trial with tigecycline in AML patients were discouraging 
[84], as no significant clinical response was observed in any of the patients at the end of the 
trial. Tigecycline treatment did not affect the expression of mitochondrial-encoded proteins in 
24 out of 27 patients, indicating that the concentration achieved in AML patients was not 
sufficient to be effective and hit its target. Accordingly, the steady-state levels of tigecycline 
reported were around 1µM, a concentration that has minimum effect on mitochondrial 
metabolism in vitro [85]. The development of a more stable formulation [86] to sustain an 
effective plasma concentration support further investigations with tigecycline in the near 
future. Of note, the outcome of a study using tigecycline in combination with TKI and in a 
different population of patients might be different to the previously mentioned clinical trial, 
as tigecycline was used as a single agent in highly refractory AML patients.  
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Importantly, both CML blast crisis cells and AML stem cells exhibit increased fatty acid 
oxidation and high OXPHOS gene signature that provides resistance to chemotherapy [11, 
87]. Since both of these diseases have a “high mutator” phenotype and are highly resistant to 
standard therapies, the reliance on oxidative metabolism provides a rational to test OXPHOS 
inhibitors as a strategy for targeting leukaemic cells with alternative resistant mechanisms, 
including BCR-ABL-independent mechanisms. Moreover, these studies open up new 
opportunities to test other OXPHOS inhibitors that could be useful in targeting therapy-
resistant CML cells such as VLX600 [88], Gamitrinib [89] and Etomoxir [90]. 
 
Future questions and concluding remarks 
Inhibiting autophagy or mitochondrial metabolism in combination with TKI treatment 
represents potential clinical strategies to eliminate therapy-resistant LSCs in CML patients 
with MRD. Therefore, understanding the role of these two processes in LSCs and in normal 
HSCs is essential to develop effective and safe therapeutic approaches.  
 
Although it has been shown that autophagy functions as a protective mechanism for cancer 
cells following therapy, it is important to consider that many of these studies were performed 
in vitro and the effect on autophagy was often measured after short time points. In LSCs, 
autophagy levels are upregulated compared to more mature cells suggesting that basal 
autophagy is a critical regulator of LSCs maintenance. Such evidence provides a rationale to 
test novel autophagy inhibitors in both pre-clinical and clinical settings in an attempt to 
eliminate LSCs. Of note, in our in vivo studies we observed a reduction in LSCs following 
BCR-ABL and autophagy inhibition compared to TKI as a single agent. As mice were treated 
for three weeks, these results suggest that the eradication of LSCs might be progressive and 
not due to a rapid cytoprotective response mediated by BCR-ABL inhibition. Whether more 
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selective autophagy inhibitors would achieve more potent effects than Lys05 in relation to 
inducing in vivo differentiation of LSCs is a question that remains to be fully answered. In 
addition, it is very likely that, inside the bone marrow, other survival mechanisms might be 
protecting LSCs from therapeutic insults. LSCs reside within an adapted niche that renders 
them resistant to therapy [91]. Interestingly, autophagy is currently emerging as an important 
process for the interaction between cancer cells and the stroma [92, 93]. The role autophagy 
plays in mesenchymal cells in the leukemic niche would be an important factor to consider in 
the context of future studies that aim to elucidate the mechanisms underlying LSCs 
maintenance. In this regard, the anti-tumour effects of systemic loss of autophagy is greater 
than specific autophagy loss in tumour cells, suggesting that both host autophagy and cell-
autonomous autophagy contribute to tumour growth [94].  
 
Importantly, an alternative process of autophagy can occur independently of the hierarchical 
activity of ATG proteins; named non-canonical autophagy [95]. This indicates that 
therapeutic strategies targeting canonical autophagy proteins might be bypassed by non-
canonical mechanisms. As both forms of autophagy rely on the lysosomes for the degradation 
of cytoplasmic material, the use of lysosomotropic agents such as Lys05 or dimeric 
quinacrines could be the best choice as an autophagy targeting approach, despite their broad 
effect.  
 
In addition, the metabolic effects on LSCs following TKI treatment would be particularly 
interesting to address in future studies. Although studies have provided some indications 
about this regulation, all of these experiments were performed in vitro, and further 
investigations should take advantage of the state-of-the-art Scl-tTa–BCR-ABL model [96] to 
compare the metabolic differences between stem cells isolated from long-term TKI-treated 
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and untreated mice. Likewise, the contribution of the bone marrow microenvironment to the 
aberrant metabolism of LSCs remains an avenue for further investigations. Such questions 
can be addressed using relevant co-culture and 3D in vitro culture systems; however, directly 
measuring aberrant metabolism in vivo as a result of an altered microenvironment remains 
technically challenging. Interestingly, recent studies showed that LSCs can uptake 
mitochondria from stromal cells by endocytosis, leading to an increase in chemotherapy 
resistance [97]. Given that BCR-ABL
+ 
cells can alter neighbouring BCR-ABL
- 
hematopoietic 
progenitor cells [98], studying whether leukaemic cells are modulating the metabolism of 
BCR-ABL
-
 cells through mitochondria transfer represents another attractive area for further 
investigation.   
 
In conclusion, recent pre-clinical CML studies are paving the way to use second-generation 
autophagy inhibitors and OXPHOS inhibitors in CML clinical trials. However, our 
understanding of the role and connection of autophagy and mitochondrial metabolism in the 
regulation of LSCs is in its infancy. Future pre-clinical and clinical studies will provide 
further information about the therapeutic value of targeting autophagy and mitochondrial 
metabolism in CML. 
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Figure 1: Potential Mechanisms Regulating Autophagy in LSCs. BCR-ABL driven canonical 
signalling results in the activation of AKT and mTOR complex 1 (mTORC1). mTORC1 
activation phosphorylates ULK1 leading to the inhibition of autophagy. Additional 
mechanisms are in place to allow autophagy activation in the presence of activated mTORC1. 
High levels of reactive oxygen species (ROS) driven by BCR-ABL potentially results in an 
oxidative stress mediated activation of autophagy. ROS can enhance autophagy directly or 
indirectly through AMPK activation. Further, TGFβ signalling blocks AKT inactivation of 
FOXO3A, leading to their re-localization from the cytoplasm (inactive) to the nucleus 
(active). Nuclear FOXO3A allows transcription of autophagy genes and a resultant activation 
of the autophagy process.  
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Figure 2: Interplay between autophagy, mitochondrial metabolism and ROS in HSCs 
and LSCs. Higher levels of reactive oxygen species (ROS) in leukemic stem cells (LSC), 
compared with normal haematopoietic stem cells (HSC), might derive from increased 
mitochondrial metabolism in LSCs. Autophagy can be up-regulated by an increase in ROS, 
maintaining oxidative stress below a certain level, in order to prevent ROS-induced 
differentiation. Additionally, AMPK can be activated by ROS, resulting in a cycle where 
AMPK might be modulating ROS levels directly, and/or indirectly through autophagy 
induction. 
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Figure 3: Targeting LSCs with 2nd generation autophagy inhibitors. Chronic myeloid 
leukemia stem cells (LSCs) have high levels of autophagy compared to normal 
haematopoietic stem cells.  The use of second-generation autophagy inhibitors selectively 
targets LSCs driving them into differentiation, potentially by increasing oxidative stress. 
Tyrosine kinase inhibitors (TKI) target the more differentiated, proliferating cell population. 
Therefore, using second-generation autophagy inhibitors to drive cells towards a more 
differentiated phenotype should allow these cells to be targeted by TKI. 
